Search results

2371 results

Sorted by Relevance . Sort by Date

  1. Effect of specialist services on health-related quality of life:- For people who have experienced suspected anaphylaxis, what is the effect on health-related quality of life of (a) referral to specialist allergy services and (b) provision of adrenaline injectors, when compared with emergency treatment alone?

    Recommendation ID CG134/5 Question Effect of specialist services on health-related quality of life:- For people who have experienced suspected

  2. Further research into whether concomitant dacarbazine enhances the clinical effectiveness of ipilimumab would be encouraged because it could provide information for future treatment strategies, as would more data on the relative effectiveness of ipilimumab when given as a first-line or second-line treatment.

    Recommendation ID TA319/2 Question Further research into whether concomitant dacarbazine enhances the clinical effectiveness of ipilimumab

  3. Further research is needed on the impact of faecal calprotectin testing on clinical decision-making when added to current practice. This includes research into optimal cut-off values for tests and the investigation of repeat testing strategies in people with intermediate levels of faecal calprotectin. Development of a consistent definition for the 'intermediate range' is encouraged.

    Recommendation ID DG11/2 Question Further research is needed on the impact of faecal calprotectin testing on clinical decision-making when

  4. Further research is recommended on clinical outcomes associated with using the ELISA kits (LISA-TRACKER, IDKmonitor and Promonitor) in people whose Crohn's disease is losing response to a TNF-alpha inhibitor. This could be through a prospective study, for local audit, or for submission to a registry. (The IBD Registry is being adapted to receive data on TNF-alpha inhibitor levels and antibodies against TNF-alpha inhibitors).

    Recommendation ID DG22/2 Question Further research is recommended on clinical outcomes associated with using the ELISA kits (LISA-TRACKER

  5. Further research is recommended on clinical outcomes associated with using the ELISA kits (LISA-TRACKER, IDKmonitor and Promonitor) to monitor TNF-alpha-inhibitor levels and antibodies to a TNF-alpha inhibitor in people with Crohn's disease whose disease responds to treatment with TNF-alpha inhibitors. This should be evaluated using prospective studies.

    Recommendation ID DG22/3 Question Further research is recommended on clinical outcomes associated with using the ELISA kits (LISA-TRACKER

  6. Further research is recommended on the use of repeat PlGF-based testing (Triage PlGF test and Elecsys immunoassay sFlt-1/PlGF ratio), with standard clinical assessment, in women presenting with suspected pre-eclampsia between 20 weeks and 34 weeks plus 6 days of gestation, who have had a negative PlGF-based test result (Triage PlGF test result of 100 picograms/ml or more; Elecsys immunoassay sFlt 1/PlGF ratio of less than 38) that was used to rule-out pre-eclampsia. This should include:- exploration of the different scenarios in which repeat testing may be indicated- the appropriate intervals between PlGF-based tests- the diagnostic accuracy of PlGF-based testing in women with suspected pre-eclampsia who have previously had 1 or more negative PlGF-based test results.

    Recommendation ID DG23/1 Question Further research is recommended on the use of repeat PlGF-based testing (Triage PlGF test and Elecsys

  7. Further research is recommended on the use of the Triage PlGF test and Elecsys immunoassay sFlt-1/PlGF ratio, with standard clinical assessment, to rule-in pre-eclampsia in women presenting with suspected pre-eclampsia between 20 weeks and 34 weeks plus 6 days of gestation. This should specifically investigate how a positive PlGF-based test result (Triage PlGF test result of 12 picograms/ml or less; Elecsys immunoassay sFlt 1/PlGF ratio of greater than 38) used to rule-in pre-eclampsia would affect management decisions on time to delivery and the outcomes associated with this.

    Recommendation ID DG23/2 Question Further research is recommended on the use of the Triage PlGF test and Elecsys immunoassay sFlt-1/PlGF

  8. Further research is recommended on using ImmunoCAP ISAC 112 for diagnosing allergy and clinical outcomes associated with using allergy testing for people with allergy that is difficult to diagnose, specifically in people with:- idiopathic anaphylaxis- multiple allergies and multiple sensitisations- plant-derived food allergy- seafood allergy, but who have a positive history and negative diagnostic test results.

    Recommendation ID DG24/2 Question Further research is recommended on using ImmunoCAP ISAC 112 for diagnosing allergy and clinical outcomes

  9. Further diagnostic accuracy studies, or analyses of existing data sets, are recommended to assess the accuracy of the tests included in this assessment in the following subgroups:- people who are premenopausal- people who are postmenopausal- people with suspected early stage ovarian cancer, that is, disease apparently confined to the pelvis.Future studies should be done in populations that are representative of people with suspected ovarian cancer who are assessed in NHS secondary care.

    Recommendation ID DG31/1 Question Further diagnostic accuracy studies, or analyses of existing data sets, are recommended to assess the

  10. Further research and data collection for inserting a balloon device to disimpact an engaged fetal head before an emergency caesarean section should report the impact of performing the procedure on the time taken from the decision to perform a caesarean section to delivery of the baby. Technical failures, including the need for repositioning of the device and for subsequent manual disimpaction of the fetal head; and any complications resulting from use of the procedure should be recorded. Fetal outcomes should also be reported. NICE may update the guidance on publication of further evidence.

    Recommendation ID IPG515/1 Question Further research and data collection for inserting a balloon device to disimpact an engaged fetal

  11. Further research and publication of observational data would be useful. Publications should describe details of patient selection, particularly in relation to previous treatments. They should also describe clinical outcomes (including all complications) and patient experience in the longer term. NICE may review the procedure on publication of further evidence.

    Recommendation ID IPG439/1 Question Further research and publication of observational data would be useful. Publications should describe

  12. Further research, ideally in the form of randomised controlled trials, on the safety and efficacy of prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia should report details of patient selection (including prostate size and the amount of median lobe enlargement), improvement in lower urinary tract symptoms in the short term and long term, re-intervention rates, and outcome measures of sexual function using established methods.

    Recommendation ID IPG641/1 Question Further research, ideally in the form of randomised controlled trials, on the safety and efficacy of

  13. Further research in people who could have conventional cardiac pacemaker implantation should report the patient selection criteria and compare leadless pacemakers with conventional pacemakers. Follow-up should be for at least 5 years and outcomes should include adverse events, symptom relief, quality of life and device durability in the long-term.

    Recommendation ID IPG626/1 Question Further research in people who could have conventional cardiac pacemaker implantation should report